CuraTeQ Biologics completes Phase 3 clinical study for Denosumab biosimilar
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Transform healthcare by integrating expertise from AI, clinical sciences, and basic sciences to harness India’s extensive data sets for improving the access to healthcare
Subscribe To Our Newsletter & Stay Updated